Dipyridamole is a
drug that inhibits thrombus formation when given chronical and causes
vasodilatation when given at high doses over short time.It inhibits the cellular reuptake of
adenosine into platelets,
red blood cells and
endothelial cells leading to increased extracellular concentrations of adenosine.It also inhibits the
enzyme adenosine deaminase which normally breaks down
adenosine into
inosine. This inhibition leads to further increased levels of extracellular adenosine.Dipyridamole also inhibits the enzyme
phosphodiesterase- 5 (PDE 5) which normally breaks down
cGMP. This results in added benefit when given together with NO or statins. Dipyridamole has shown to lower pulmonary hypertension without significant drop of systemic blood pressureDipyridamole inhibits formation of pro-inflammatory cytokines (MCP-1, MMP-9) in vitro and results in reduction of hsCRP in patients.Dipyridamole inhibits proliferation of smooth muscle cells in vivo and has shown to prevent AV-shunt failure in dialysis patients.Dipyridamole increases release of t-PA from brain microvascular endothelial cells Dipyridamole treatment in vivo results in increase of 13 - HODE and decrease of 12 - HETE in the subendothelial matrix (SEM) and reduced thrombogenicity of the SEM. Dipyridamole pretreatment reduced reperfusion injury in volunteers.Dipyridamole treatment has shown to increase myocardial perfusion and left ventricular function in patients with ischemic cardiomyopathy.Dipyridamole treatment resulted in reduction of the number of thrombin and PECAM-1 receptors on platelets in stroke patients.Adenosine interacts with the adenosine receptors to cause increased cAMP via
adenylate cyclase.cAMP impairs platelet aggregation and also causes
arteriolar smooth muscle relaxation. Chronic therapy did not show significant drop of systemic blood pressure.
See more at Wikipedia.org...
Free Download Now!
